The San Francisco Department of Public Health continues to see concerning rises in sexually transmitted infections (STIs). This half-day, virtual event will provide important updates in the field of sexual health to help providers strengthen the delivery of STI prevention and care. Hear from local experts on STI epidemiology in San Francisco, important recommendations to prevent congenital syphilis, updates from the 2021 CDC STI Treatment Guidelines, and a lively case panel

Save the date for the annual San Francisco STI Update on November 4th, 2021!

This web-based, half-day morning event will include presentations from STI experts in San Francisco and cover topics such as STI epidemiology, addressing rising syphilis rates, and highlights from the new 2021 CDC STI Treatment Guidelines. Learn from the experts as our clinician panel addresses challenging cases on the fly. Lookout for more details and registration information coming soon. While all providers and program staff are welcome to register, we will be focusing on San Francisco based data and recommendations.

On July 22nd the Centers for Disease Control and Prevention (CDC) released the Sexually Transmitted Infections (STI) Treatment Guidelines, 2021. These updated guidelines provide evidence-based recommendations on the prevention, diagnosis, and treatment of STIs. Provider resources include a downloadable wall chart and pocket guide.  A new mobile app is coming soon. Key treatment updates include:
In 2019, SFDPH was awarded with a grant to develop a local “end the HIV epidemic” plan as part of the national Ending the HIV Epidemic Initiative, which aims to reduce the number of new HIV acquisitions in the U.S. by at least 90 percent by 2030. In response, SFDPH and community partners developed the SF Ending the HIV/HCV/STI Epidemics (SF ETE) Plan as a roadmap for how SF could address this syndemic
The YUTHE Program is a professional development and peer education internship designed to introduce youth and young adults to the field of public health and address health disparities in San Francisco, specifically in regard to substance use and sexual health. The YUTHE program conducts sexual health workshops at local high schools and community-based organizations and provides street outreach to youth in the Bayview, Castro, Fillmore, and Visitation Valley neighborhoods. During outreach they discuss topics such as healthy relationships, STIs, and PrEP while distributing safer sex supplies and information.
As of April 1, 2021, multiple generics for emtricitabine/tenofovir DF 200/300mg (TDF/FTC, brand-name Truvada) have entered the market and driven costs down tremendously. Therefore, even full cash pay should not cost more than $40/month in SF. Prices are not yet consistent across all pharmacies, and some pharmacies may continue to quote prices as high as >$1,000+. Most should not need to pay cash, but for those who do, a solid plan is to prescribe to a pharmacy that you know consistently stocks a low-price generic. Plan B: check GoodRx.com.
Due to the COVID-19 pandemic, access to sexual health services declined significantly in 2020, reflected in a 40% decline in HIV and STI testing in San Francisco.  The COVID-19 pandemic challenged us to be more innovative in how to offer these much-needed services.  In 2020, San Francisco City Clinic implemented tele-health and express visits to serve as many patients as quickly and safely as possible, and continues to offer low-cost STI testing, diagnosis, and treatment regardless of insurance status.  To make sexual health care even more accessible, SFDPH has launched a home HIV/STI testing program, TakeMeHome, which provides San Franciscans with access to FREE HIV and STI screening in the privacy of their own home.

California has recently experienced increases in reports of disseminated gonococcal infection (DGI), a severe complication of untreated gonorrhea. 

DGI occurs when gonorrhea invades the bloodstream and spreads to distant sites in the body, leading to clinical manifestations such as septic arthritis, polyarthralgia, tenosynovitis, petechial/pustular skin lesions, bacteremia, or, on rare occasions, endocarditis or meningitis.